Nghiên cứu PSMA-PET/CT để giải quyết không nhất quán giữa MRI tuyến tiền liệt PIRAD4-5 và sinh thiết âm tính

Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH et al (2018) MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 378(19):1767–1777 Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK et al (2017) Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. The Lancet 389(10071):815–822 Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ et al (2019) Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol 76(3):340–351 Kam J, Yuminaga Y, Krelle M, Gavin D, Koschel S, Aluwihare K et al (2019) Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study. BJU Int 124(2):297–301 Purysko AS, Bittencourt LK, Bullen JA, Mostardeiro TR, Herts BR, Klein EA (2017) Accuracy and interobserver agreement for prostate imaging reporting and data system, version 2, for the characterization of lesions identified on multiparametric MRI of the prostate. AJR Am J Roentgenol 209(2):339–349 Brembilla G, Dell’Oglio P, Stabile A, Damascelli A, Brunetti L, Ravelli S et al (2020) Interreader variability in prostate MRI reporting using prostate imaging reporting and data system version 2.1. Eur Radiol 30(6):3383–3392 Moldovan PC, Van den Broeck T, Sylvester R, Marconi L, Bellmunt J, van den Bergh RCN et al (2017) What is the negative predictive value of multiparametric magnetic resonance imaging in excluding prostate cancer at biopsy? A systematic review and meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. Eur Urol 72(2):250–266 Lo G, Burton KR, Haider MA, Fleshner N, Finelli A, Ghai S (2019) Negative predictive value of prostate multiparametric magnetic resonance imaging among men with negative prostate biopsy and elevated prostate specific antigen: a clinical outcome retrospective cohort study. J Urol 202(6):1159–1165 Whish-Wilson T, Costello D, Finch S, Sutherland T, Wong LM (2020) Funding of prostate magnetic resonance imaging leads to fewer biopsies and potential savings to health systems in the management of prostate cancer: funding prostate MRI has potential savings. BJU Int. https://doi.org/10.1111/bju.15231 Tsourlakis MC, Klein F, Kluth M, Quaas A, Graefen M, Haese A et al (2015) PSMA expression is highly homogenous in primary prostate cancer. Appl Immunohistochem Amp Mol Morphol AIMM 23(6):449–455 Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P et al (2020) Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. The Lancet 395(10231):1208–1216 Perera M, Papa N, Roberts M, Williams M, Udovicich C, Vela I et al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer—updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77(4):403–417 Perry E, Talwar A, Taubman K, Ng M, Wong LM, Booth R et al (2021) [18F]DCFPyL PET/CT in detection and localization of recurrent prostate cancer following prostatectomy including low PSA < 0.5 ng/mL. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-020-05143-9 Koschel S, Taubman K, Sutherland T, Yap K, Chao M, Guerrieri M et al (2021) Patterns of disease detection using [18F]DCFPyL PET/CT imaging in patients with detectable PSA post prostatectomy being considered for salvage radiotherapy: a prospective trial. Eur J Nucl Med Mol Imaging. https://doi.org/10.1007/s00259-021-05354-8 Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D et al (2021) Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, Multicenter Study. Clin Cancer Res 27(13):3674–3682 Amin A, Blazevski A, Thompson J, Scheltema MJ, Hofman MS, Murphy D et al (2020) Protocol for the PRIMARY clinical trial, a prospective, multicentre, cross-sectional study of the additive diagnostic value of gallium-68 prostate-specific membrane antigen positron-emission tomography/computed tomography to multiparametric magnetic resonance imaging in the diagnostic setting for men being investigated for prostate cancer. BJU Int 125(4):515–524 Tran V, Hong A, Sutherland T, Taubman K, Lee SF, Lenaghan D et al (2022) PEDAL protocol: a prospective single-arm paired comparison of multiparametric MRI and 18F-DCFPyl PSMA PET/CT to diagnose prostate cancer. BMJ Open 12(9):e061815 Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al (2021) The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol Dec 80(6):682–689 Margel D, Bernstine H, Groshar D, Ber Y, Nezrit O, Segal N et al (2021) Diagnostic performance of 68Ga prostate-specific membrane antigen PET/MRI compared with multiparametric MRI for detecting clinically significant prostate cancer. Radiology 301(2):379–386 Berger I, Annabattula C, Lewis J, Shetty DV, Kam J, Maclean F et al (2018) 68Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology. Prostate Cancer Prostatic Dis 21(2):204–211 Kalapara AA, Nzenza T, Pan HYC, Ballok Z, Ramdave S, O’Sullivan R et al (2020) Detection and localisation of primary prostate cancer using 68 gallium prostate-specific membrane antigen positron emission tomography/computed tomography compared with multiparametric magnetic resonance imaging and radical prostatectomy specimen pathology. BJU Int 126(1):83–90 Panicek DM, Hricak H (2016) How sure are you, doctor? A standardized lexicon to describe the radiologist’s level of certainty. Am J Roentgenol 207(1):2–3 National Cancer Institute. NCI Common Terminology Criteria for Adverse Events 2017. https://evs.nci.nih.gov/ftp1/CTCAE/About.html Ptasznik G, Papa N, Kelly BD, Thompson J, Stricker P, Roberts MJ, et al (2022) High PSMA PET SUVmax in PI-RADS 4 or 5 men confers a high probability of significant prostate cancer. BJU Int 130 (Suppl 3):5–7 Emmett LM, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al (2022) The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. J Nucl Med 63(11):1644–1650. https://doi.org/10.2967/jnumed.121.263448 Meng X, Chao B, Chen F, Huang R, Taneja SS, Deng FM (2021) Followup of men with PI-RADS™ 4 or 5 abnormality on prostate magnetic resonance imaging and nonmalignant pathological findings on initial targeted prostate biopsy. J Urol 205(3):748–754 Gaziev G, Wadhwa K, Barrett T, Koo BC, Gallagher FA, Serrao E et al (2016) Defining the learning curve for multiparametric magnetic resonance imaging (MRI) of the prostate using MRI-transrectal ultrasonography (TRUS) fusion-guided transperineal prostate biopsies as a validation tool. BJU Int 117(1):80–86 Greer MD, Shih JH, Lay N, Barrett T, Bittencourt L, Borofsky S et al (2019) Interreader variability of prostate imaging reporting and data system version 2 in detecting and assessing prostate cancer lesions at prostate MRI. Am J Roentgenol 212(6):1197–1205 Müller S, Lilleaasen G, Sand TE, Løfsgaard L, Estop-Garanto M, Helgø D et al (2018) Poor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA. World J Urol 36(5):687–691 Wegelin O, van Melick HHE, Hooft L, Bosch JLHR, Reitsma HB, Barentsz JO et al (2017) Comparing three different techniques for magnetic resonance imaging-targeted prostate biopsies: a systematic review of in-bore versus magnetic resonance imaging-transrectal ultrasound fusion versus cognitive registration. Is there a preferred technique? Eur Urol 71(4):517–531